Long-Term Outcome after Early Mammalian Target of Rapamycin Inhibitor-Based Immunosuppression in Kidney Transplant Recipients.

Autor: Liefeldt L; Department of Nephrology and Internal Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Campus Charité Mitte, Charitéplatz 1, 10117 Berlin, Germany., Waiser J; Department of Nephrology and Internal Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Campus Charité Mitte, Charitéplatz 1, 10117 Berlin, Germany., Bachmann F; Department of Nephrology and Internal Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Campus Charité Mitte, Charitéplatz 1, 10117 Berlin, Germany., Budde K; Department of Nephrology and Internal Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Campus Charité Mitte, Charitéplatz 1, 10117 Berlin, Germany., Friedersdorff F; Department of Urology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany., Halleck F; Department of Nephrology and Internal Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Campus Charité Mitte, Charitéplatz 1, 10117 Berlin, Germany., Lachmann N; Centre for Tumor Medicine, H&I Laboratory, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany., Peters R; Department of Urology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany., Rudolph B; Department of Pathology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany., Ünlü S; Centre for Tumor Medicine, H&I Laboratory, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany., Wu K; Department of Nephrology and Internal Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Campus Charité Mitte, Charitéplatz 1, 10117 Berlin, Germany., Glander P; Department of Nephrology and Internal Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Campus Charité Mitte, Charitéplatz 1, 10117 Berlin, Germany.
Jazyk: angličtina
Zdroj: Journal of clinical medicine [J Clin Med] 2024 Jul 23; Vol. 13 (15). Date of Electronic Publication: 2024 Jul 23.
DOI: 10.3390/jcm13154305
Abstrakt: Background: The use of mammalian target of rapamycin inhibitors (mTORis) in kidney transplantation increases the risk of donor-specific human leukocyte antigen (HLA) antibody formation and rejection. Here, we investigated the long-term consequences of early mTORi treatment compared to calcineurin inhibitor (CNI) treatment. Methods: In this retrospective single-center analysis, key outcome parameters were compared between patients participating in randomized controlled immunosuppression trials between 1998 and 2011, with complete follow-up until 2018. The outcomes of eligible patients on a CNI-based regimen (n = 384) were compared with those of patients randomized to a CNI-free mTORi-based regimen (n = 81) and 76 patients randomized to a combination of CNI and mTORi treatments. All data were analyzed according to the intention-to-treat (ITT) principle. Results: Deviation from randomized immunosuppression for clinical reasons occurred significantly more often and much earlier in both mTORi-containing regimens than in the CNI treatment. Overall patient survival, graft survival, and death-censored graft survival did not differ between the treatment groups. Donor-specific HLA antibody formation and BPARs were significantly more common in both mTORi regimens than in the CNI-based immunosuppression. Conclusions: The tolerability and efficacy of the mTORi treatment in kidney graft recipients are inferior to those of CNI-based immunosuppression, while the long-term patient and graft survival rates were similar.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje